GHK-Cu: What People Actually Pay, Real Results, and the Clinical Evidence Behind the Hype
HealthRX.com
Personal reports are mixed and human trials are small
Key numbers
- 0.4%Copper peptide cream strength in the venous ulcer trial, which was no better than placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- P=.04Patient questionnaire result favoring GHK-Cu for overall skin quality after CO2 laser resurfacingSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 12 weeksTime after laser resurfacing when the patient questionnaire was completedSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- FDA-approved GHK-Cu drugs / None [3]
- Topical copper peptide products / Sold as cosmetics; generally no FDA approval needed before sale [4]
- Injectable GHK-Cu / Unapproved; FDA lists it as nominated but withdrawn, citing immunogenicity risk [5]
- Non-injectable compounding status / Category 1, under evaluation for the compounding bulks list [3][6]
- Venous ulcer trial / 86 evaluable patients; cream no better than placebo [1]
- Laser-resurfacing trial / 13 patients; objective measures negative, patient questionnaire positive [2]
- Human literature overall / Described as thin and fragmented in a 2026 systematic review [7]
What forms of GHK-Cu are sold, and how are they regulated?
GHK-Cu is sold in different forms with different regulatory treatment. Topical serums and creams sold as cosmetics do not need FDA approval before sale, because cosmetics and cosmetic ingredients other than color additives do not need it [4]. Non-injectable GHK-Cu as a bulk substance for compounding is in FDA category 1, the group under evaluation for the bulks list [3][6]. Injectable GHK-Cu is not a cosmetic, is not FDA-approved, and appears on FDA's list of nominated-but-withdrawn bulk substances with a stated immunogenicity concern [4][5].
Is any GHK-Cu product FDA-approved?
No. No FDA-approved drug is known to contain GHK-Cu [3]. It is easy to confuse with copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children; that is a different compound [3][8].
Whether a product is a cosmetic or a drug turns on intended use: claims to treat disease or to change the structure or function of the body make it a drug [4]. An injectable GHK-Cu product is not a cosmetic, and it is not FDA-approved [4].
What do FDA's compounding lists say right now?
Non-injectable GHK-Cu is in category 1, listed as 'GHK-Cu (except for injectable routes of administration)' [3][6]. FDA says it generally does not intend to act against compounders for category 1 substances when the conditions in its guidance are met [6]. The listing has moved: it was removed on April 22, 2026 when the nominations were withdrawn, a nominator clarified on May 5, 2026 that only the injectable route had been withdrawn, and FDA added non-injectable GHK-Cu back on its list updated May 14, 2026 [3]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether to include GHK-Cu on the bulks list; no vote has happened yet [3].
Injectable GHK-Cu sits elsewhere. On FDA's page about bulk substances that may raise significant safety risks when compounded (content dated 04/22/2026), 'GHK-Cu (for injectable routes of administration)' appears in the nominated-but-withdrawn table. FDA's stated concern: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.' [5] Injectable GHK-Cu is not in category 1 and is not in any category on FDA's current list [3].
Two more status points: GHK-Cu is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy, which covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [9], and it is not on FDA's list for outsourcing facilities (updated March 21, 2025) [10]. Compounded drugs generally are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [11].
What do the human trials actually show?
The randomized human trials found tested a cream for venous ulcers and skin care after CO2 laser resurfacing.
The venous ulcer trial, by Bishop and colleagues in the Journal of Vascular Surgery in 1992, was a prospective randomized evaluator-blinded study in which 86 evaluable patients with venous stasis ulcers completed treatment. Silver sulfadiazine 1% cream reduced ulcer size compared with the placebo; the 0.4% tripeptide copper complex cream was no different from placebo [1].
The laser trial, by Miller and colleagues in Archives of Facial Plastic Surgery in 2006, randomized patients whose skin around the mouth had been resurfaced with a CO2 laser to post-treatment skin care with or without GHK-Cu; 13 patients completed. Computer analysis and blinded evaluators found no significant difference in how quickly redness resolved, in wrinkles, or in overall skin quality. A validated patient questionnaire completed 12 weeks after treatment did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [2].
A 2026 systematic review searched the literature from 2005 to 2026, screened 1,247 records and retained 64 for qualitative synthesis. Its authors write that despite four decades of preclinical work the human literature 'remains thin and fragmented,' that most randomized trials are small and run on facial cosmetic creams, and that microneedle delivery has not been evaluated in a single registered, adequately powered human randomized controlled trial [7].
What people on Reddit report
Personal accounts of skin use from forum threads. Reports are mixed: some say texture and fine lines improved, while others report dullness, breakouts or sagging, often at high daily doses.
I use GHK-Cu for skin and have noticed improvement in texture and fine lines. It does work but consistency is key.Read the source discussion
But I have noted subtle, promising changes in skin thickness and density, which helps with laxity a bit, as well as texture -- subtle improvements to my early nasolabial folds, etc.Read the source discussion
Questions worth asking
What does the laboratory and animal work show?
The proposed mechanisms come from lab and animal studies, summarized by the researchers who advanced them: GHK is reported to stimulate collagen and proteoglycan synthesis, modulate metalloproteinases and their inhibitors, attract immune and endothelial cells to injury sites, and accelerate wound healing in dogs, rats, mice and pigs [12]. A 2015 review by the same group describes cosmetic-product effects such as firmer skin and fewer fine lines, alongside gene-expression findings, but it is a narrative review, not a randomized trial [12]. A 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences covers the peptide's broader regenerative claims; it too is a review [13]. These are preclinical or proposed mechanisms, not proven human effects.
Individual animal experiments are consistent with that summary. In a 2006 study, 18 New Zealand rabbits with full-thickness wounds were treated with a tripeptide-copper complex, zinc oxide, or nothing; the unhealed wound area was significantly smaller in the copper group than in the untreated controls on days 7, 14 and 21 [14].
For hair, the evidence found is also animal work. A 1993 report described follicular enlargement in fuzzy rats with a copper binding peptide called PC1031, an effect similar to topical minoxidil [15].
What strengths were used in the studies?
No FDA-approved drug is known to contain GHK-Cu, so there is no approved dose [3]. The venous-ulcer trial tested a 0.4% tripeptide copper complex cream [1]. Topical cosmetic strengths are set by manufacturers and are not FDA-reviewed [4].
What are the known safety concerns?
For injectable GHK-Cu, FDA flags a possible immunogenicity risk and says there are limited data in humans to inform safety-related considerations [5]. The abstracts of the two human trials above do not give adverse-event rates for the topical products [1][2].
Dr Dray on why injectable GHK-Cu carries unproven risks
Dr Dray argues that GHK-Cu has real biological activity and a plausible role in wound healing and tissue repair, but that the evidence is mostly from cell and animal studies rather than human trials. She is skeptical of influencer claims about collagen, hair growth and longevity, and sees the human trials as too small to support them. Her main concern is injection. In her view, peptides sold for injection through compounding pharmacies or research chemical websites are not FDA-approved, lack standardized dosing and human safety data, and carry risks of impurity and contamination. She sees topical use as low risk but of modest effect, and she advises viewers to look at the actual research before following a trend.
Who is speaking?
Dr Dray. Board-certified dermatologist, as described in the video and on the channel Background
Is GHK-Cu on the banned lists for athletes?
GHK-Cu is not named on WADA's 2026 Prohibited List or the 2027 List [16][17]. WADA's S0 class covers substances with no approval from any governmental health authority, and the 2027 explanatory notes say peptides not specifically named may still be prohibited, so athletes should check with their anti-doping organization rather than assume it is permitted [16][17].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is GHK-Cu FDA-approved?
What is the difference between the GHK-Cu forms on the market?
Do human trials show that GHK-Cu works?
What strength of GHK-Cu was tested in humans?
What does FDA say about injectable GHK-Cu?
Is GHK-Cu banned in sport?
References
Show all 20 referencesHide references
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9.
- U.S. Food and Drug Administration.
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Bulk Drug Substances Used in Compounding | FDA.
- Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293.
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- Official web page.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7).
- Cangul IT, Gul NY, Topal A, Yilmaz R. Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol. 2006;17(6):417-23.
- Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993;101(1 Suppl):143S-147S.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Reddit participants. [product question] has anyone tried GHK-CU injections for skin care ( improving skin texture and reducing fine lines and wrinkles) and if so (r/SkincareAddiction). Accessed 2026-11-11.
- Reddit participants. Anyone tried injectable GHK CU? Total game changer for skin care (r/30PlusSkinCare). Accessed 2026-11-11.
- Dr Dray. Injectable Peptides for Anti-Aging? A Dermatologist Explains GHK-Cu. Accessed 2026-11-11.